Incyte Completes $1.25 Billion Acquisition of Vega Therapeutics, Expanding Hematology Portfolio with Late-Stage von Willebrand Disease Therapy VGA039
Incyte has announced the successful completion of its acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC, marking a significant expansion of the company’s hematology portfolio. The transaction brings VGA039, an investigational monoclonal antibody currently in Phase 3 clinical development for von Willebrand disease (VWD), under Incyte’s ownership and strengthens the company’s position in the growing field of hematologic disorders.
The acquisition represents an important strategic milestone for Incyte as it broadens its presence beyond oncology and established hematology indications into inherited bleeding disorders. VGA039 is considered one of the most advanced investigational therapies currently in development for von Willebrand disease and has the potential to become the first once-monthly subcutaneous prophylactic treatment specifically designed for patients living with the condition.
The company stated that its immediate priority is to continue advancing the ongoing Phase 3 clinical program while integrating the Vega Therapeutics team into Incyte’s global research and development organization.
Strategic Expansion into Bleeding Disorders
Incyte has spent the past several years building a diversified portfolio of therapies across oncology, inflammation, and hematologic diseases. The addition of VGA039 expands the company’s hematology franchise into an area of significant unmet medical need.
Von Willebrand disease is the most common inherited bleeding disorder worldwide, yet treatment options remain relatively limited, particularly for patients who experience frequent bleeding episodes requiring long-term preventive therapy.
By acquiring Vega Therapeutics, Incyte gains not only a late-stage clinical asset but also expertise in novel approaches to improving blood clotting through modulation of natural anticoagulation pathways.
According to the company, VGA039 complements its existing hematology portfolio while opening opportunities to address additional bleeding disorders in the future.
Leadership Highlights Strategic Importance
Bill Meury, Chief Executive Officer of Incyte, described the completion of the acquisition as an important step in strengthening the company’s long-term growth strategy.
He noted that VGA039 represents one of the most promising late-stage hematology programs currently in development and aligns well with Incyte’s strategic focus on innovative therapies addressing serious diseases with significant unmet medical needs.
Meury stated that the company intends to prioritize advancement of the Phase 3 clinical development program while working closely with the experienced scientists and development teams joining Incyte through the acquisition.
He also emphasized that integrating Vega Therapeutics’ expertise will support continued progress toward bringing the investigational therapy to patients living with inherited bleeding disorders.
Understanding von Willebrand Disease
Von Willebrand disease is the most common inherited bleeding disorder, affecting an estimated one percent of the global population, although many individuals remain undiagnosed because symptoms can vary considerably in severity.
The disorder results from deficiencies or abnormalities involving von Willebrand factor (VWF), a blood-clotting protein that plays a critical role in helping platelets adhere to damaged blood vessels during the early stages of clot formation.
When von Willebrand factor is deficient or dysfunctional, patients experience impaired clot formation that can lead to prolonged or excessive bleeding.
Common symptoms include frequent nosebleeds, easy bruising, prolonged bleeding following surgery or dental procedures, heavy menstrual bleeding, gastrointestinal bleeding, and excessive bleeding after injury.
More severe forms of the disease can result in spontaneous bleeding episodes affecting joints, muscles, and internal organs.
Because the condition is inherited, patients often require lifelong monitoring and individualized treatment strategies.
Current Treatment Challenges
Management of von Willebrand disease varies depending on disease subtype, bleeding severity, and individual patient characteristics.
Current therapeutic options include desmopressin, replacement therapies containing von Willebrand factor concentrates, recombinant von Willebrand factor products, antifibrinolytic agents, and supportive measures during surgical procedures.
Patients requiring prophylactic therapy often receive repeated intravenous infusions of clotting factor concentrates to reduce bleeding frequency.
Although these treatments can be effective, frequent intravenous administration may present logistical challenges and impact quality of life, particularly for patients requiring long-term preventive therapy.
Consequently, there remains considerable interest in developing therapies that provide sustained protection while reducing treatment burden.
VGA039 Offers a Novel Mechanism
VGA039 represents an investigational monoclonal antibody utilizing a mechanism distinct from currently available replacement therapies.
Rather than replacing deficient clotting proteins directly, the therapy modulates Protein S, a naturally occurring anticoagulant involved in regulating blood coagulation.
Protein S normally helps prevent excessive clot formation by supporting anticoagulant pathways.
By selectively modulating Protein S activity, VGA039 is designed to improve hemostasis, enhancing the body’s natural ability to control bleeding while maintaining physiological balance within the coagulation system.
According to Incyte, this mechanism may provide therapeutic benefit across multiple bleeding disorders beyond von Willebrand disease.
The approach also has the potential to reduce dependence on repeated clotting factor replacement therapy.
Potential First-in-Class Therapy
If approved by regulatory authorities, VGA039 could become the first once-monthly subcutaneous prophylactic therapy available for patients living with von Willebrand disease.
Subcutaneous administration offers several practical advantages compared with traditional intravenous infusions.
Patients may be able to receive treatment through relatively simple injections beneath the skin rather than requiring intravenous access.
Monthly dosing could also substantially reduce treatment burden for individuals currently receiving frequent replacement therapy.
The combination of a novel mechanism, convenient route of administration, and extended dosing interval has contributed to growing interest in VGA039 among clinicians specializing in inherited bleeding disorders.
Advancing Through Phase 3 Development
VGA039 is currently being evaluated in the pivotal Phase 3 VIVID-6 clinical trial (ClinicalTrials.gov Identifier: NCT07115004).
The global study has been designed as a single-arm crossover trial investigating both safety and efficacy of monthly subcutaneous VGA039 administered as prophylactic therapy.
Importantly, the study includes patients representing every major type of von Willebrand disease, including individuals experiencing particularly high disease burden.
Researchers will evaluate whether prophylactic treatment reduces bleeding frequency while maintaining an acceptable safety profile.
Successful completion of the Phase 3 program would support potential regulatory submissions in major global markets.
Incyte has indicated that advancing the VIVID-6 study represents its highest development priority following completion of the acquisition.
Multiple FDA Expedited Designations
VGA039 has already received several important regulatory designations from the U.S. Food and Drug Administration recognizing both the seriousness of von Willebrand disease and the therapy’s potential clinical significance.
The investigational therapy has received Breakthrough Therapy designation, which is intended to expedite development of medicines demonstrating substantial improvement over available therapies for serious conditions.
The FDA has also granted Fast Track designation, facilitating more frequent interactions between the company and regulators throughout development.
Additionally, VGA039 has received orphan drug designation, recognizing its potential value in treating rare diseases.
The investigational therapy has also been awarded rare pediatric disease designation, reflecting possible future application in younger patients affected by inherited bleeding disorders.
Collectively, these regulatory designations may help accelerate clinical development and future review processes.
Financial Terms of the Acquisition
The acquisition follows terms previously disclosed by the companies.
Under the stock purchase agreement, Incyte acquired all outstanding shares of Vega Therapeutics, which previously operated as a wholly owned subsidiary of Star Therapeutics.
The transaction includes an upfront payment of $1.25 billion.
In addition, Star Therapeutics remains eligible to receive milestone payments totaling up to $750 million if specified future commercial sales targets are achieved.
These milestone provisions align a portion of the transaction value with the future commercial success of VGA039 following potential regulatory approval.
Financial Impact for Incyte
Incyte stated that the acquisition is expected to be reflected as a one-time research and development expense during both its third-quarter and full-year 2026 financial results under both Generally Accepted Accounting Principles (GAAP) and non-GAAP reporting.
While the acquisition creates a significant near-term accounting expense, the company views the transaction as a long-term strategic investment intended to strengthen future growth opportunities within hematology.
As VGA039 continues advancing through late-stage development, additional clinical and regulatory milestones are expected over the coming years.
Advisory Teams Supported the Transaction
Several financial and legal advisory firms participated in completing the acquisition.
Lazard served as financial advisor to Incyte throughout the transaction, while Goodwin Procter LLP provided legal counsel.
On behalf of Star Therapeutics, Evercore and Morgan Stanley acted as financial advisors.
Fenwick & West LLP served as legal counsel for Star Therapeutics during negotiations and completion of the agreement.
The participation of multiple leading advisory firms reflects both the size and strategic significance of the acquisition.
Strengthening Incyte’s Long-Term Hematology Strategy
The acquisition of Vega Therapeutics continues Incyte’s broader strategy of building a diversified pipeline spanning both malignant and non-malignant hematologic disorders.
Historically recognized for its oncology portfolio, Incyte has increasingly expanded into immune-mediated diseases and rare disorders through both internal research and targeted business development initiatives.
Adding a late-stage Phase 3 asset significantly strengthens the company’s development pipeline while potentially creating future commercial opportunities within rare hematology.
If approved, VGA039 could complement Incyte’s existing portfolio by addressing an entirely new patient population with substantial unmet medical need.
Completion of the Vega Therapeutics acquisition marks an important milestone for Incyte as it expands its presence into inherited bleeding disorders through the addition of VGA039, a promising Phase 3 investigational therapy for von Willebrand disease. The acquisition brings a novel mechanism of action, multiple FDA expedited regulatory designations, and the potential for the first once-monthly subcutaneous prophylactic treatment for patients living with the most common inherited bleeding disorder.
With the global Phase 3 VIVID-6 study already underway, Incyte’s immediate focus will be advancing clinical development while integrating the Vega Therapeutics team into its research organization. Should the ongoing trial confirm the encouraging clinical profile observed thus far, VGA039 could represent a significant advancement in the management of von Willebrand disease by offering patients a more convenient preventive treatment option capable of reducing bleeding episodes while lessening the burden associated with frequent intravenous therapies.
About VGA039
VGA039 is an investigational monoclonal antibody therapy with a novel mechanism of action that targets Protein S, with dual actions promoting platelet attachment and enhancing fibrin deposition to restore hemostasis. VGA039 has the potential to be a universal hemostatic therapy that can treat numerous bleeding disorders, starting with all types of von Willebrand disease (VWD) and bleeding sites.
As a subcutaneously self-administered investigational antibody therapy with a convenient once monthly dosing regimen, VGA039 has the potential to improve convenience and quality of life for patients.
About von Willebrand Disease
Von Willebrand disease (VWD) is the most common inherited bleeding disorder in which the blood does not clot properly, caused by low or defective von Willebrand factor (VWF). VWD patients may experience excessive bleeding with varying severity and frequency, negatively impacting their daily lives. Current therapies for VWD prophylaxis include factor replacement therapies requiring multiple intravenous (IV) infusions every week. Approximately 135,000 people in the United States have been diagnosed with von Willebrand disease.1
About Incyte®
Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity.